ReviewTherapeutic advances in psychopharmacology2020
Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data.
Review in Therapeutic advances in psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 224 citations in OpenAlex.
- Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies.Frontiers in psychiatry · 2022Pooled it
- Bioequivalence evaluation of two cariprazine hard capsule formulations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Cariprazine modulates affective and social behaviors through ventral striatal islands of Calleja neurons.Current zoology · 2026Article
- Case Report: Four cases for cariprazine and alcohol use disorder.Frontiers in psychiatry · 2026Article
- The potential of neuromelanin-sensitive MRI in psychiatric disorders.Neuroscience applied · 2026Review
- Eros Unleashed: A Case Series of Cariprazine-induced Hypersexuality.Indian journal of psychological medicine · 2025Article
- Cariprazine in Bipolar Disorder and Substance Use: A Dual Approach to Treatment?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Pharmacological Treatments of Negative Symptoms in Schizophrenia-An Update.Journal of clinical medicine · 2024Review
- Catatonia.Nature reviews. Disease primers · 2024Review
- A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.Frontiers in psychiatry · 2024Review
- Cariprazine in the management of emotionally unstable personality disorder in female patients: a case series.Frontiers in psychiatry · 2024Article
- Cariprazine in an Adolescent with Tourette Syndrome with Comorbid Attention Deficit Hyperactive Disorder and Depression: A Case Report.Healthcare (Basel, Switzerland) · 2023Article
- Efficacy and Safety of Clonidine in the Treatment of Acute Mania in Bipolar Disorder: A Systematic Review.Brain sciences · 2023Review
- The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders.Frontiers in psychiatry · 2023Article
- Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms.Frontiers in psychiatry · 2023Article
- Evaluation of the Effect of Cariprazine on Memory and Cognition in Experimental Rodent Models.International journal of environmental research and public health · 2022Article
- Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania.Frontiers in psychiatry · 2022Article
- Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series.Neuropsychiatric disease and treatment · 2022Article
- Symptomatic Profile of Cariprazine in the Context of ICD-11 Domains for Schizophrenia: Review of Clinically Oriented Studies: Симптоматический профиль карипразина в контексте доменов шизофрении в МКБ -11: обзор клинически ориентированных исследований.Consortium psychiatricum · 2022Review
- A case series of serious and unexpected adverse drug reactions under treatment with cariprazine.Clinical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as 'atypical' second generation antipsychotics. Originally approved for acute and maintenance treatment of schizophrenia as well as for acute mania and mixed mania/depression, cariprazine has now been approved for bipolar I depression. Additionally,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.